New cholesterolemia-lowering carboxyalkylether compound

摘要

Treatment of vascular diseases uses statin and carboxyalkylether combinations. Pharmaceutical composition comprises: (1) a carboxyalkylether (I) or its acid addition salt; (2) a statin (II) or its salt; and (3) a carrier or diluent. Independent claims are included for the following: (a) a first pharmaceutical composition comprising (I) or its acid addition salt for synergistic use with a second pharmaceutical composition comprising (II) or its salt, to achieve a hypolipidemic effect in mammals suffering from hyperlipidemia, provided that (II) is not atorvastatin or its salt. (NB. In a dependent claim the statin can be atorvastatin); (b) a first pharmaceutical composition comprising a compound of formula (I'') or its acid addition salt for synergistic use with a second pharmaceutical composition comprising (II) or its salt to achieve a hypolipidemic effect in mammals suffering from hyperlipidemia; [Image] N.B. n and m are not defined in the claims. In the disclosure: n, m = 2-5 (preferably 4 or 5). (c) a first pharmaceutical composition comprising (I) or its acid addition salt for synergistic use with a second pharmaceutical composition comprising (II) or its salt, to manage cardiac risk in mammals at risk of suffering an adverse cardiac event; (d) a kit for achieving a therapeutic effect in mammals comprising (I) or its acid addition salts and (II) or its salts in separate unit dosage forms and a container means, provided that the statin is not atorvastatin or its salt. (NB. In a dependent claim the statin can be atorvastatin); ACTIVITY : Vascular disorders; diabetes mellitus; antianginal; antiatherosclerotic; antihypertensive; antihyperlipidemic; cardiac disease MECHANISM OF ACTION : HMG-CoA reductase inhibitor; Triglyceride lowering; High density lipid lowering;.